AbbVie scores 48/100 (Making progress) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified May 2026.
That places AbbVie joint 188th of 809 companies scored, and joint 8th of 15 in Healthcare / Pharmaceuticals.
AbbVie has achieved meaningful absolute emissions reductions and maintains science-aligned near-term climate targets, but obscures its full supply chain footprint and lacks net-zero validation. Membership in climate-oppositional trade associations without alignment review, combined with $7.57B in regulatory penalties since 2000, signals weak governance despite robust operational disclosures.
Every supplier scored from public evidence like this, ranked, in 48 hours. No questionnaires, and your suppliers never know.
This score uses public evidence only. Challenge any question for free, or ask for a human review of evidence you haven't published.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Targets & Commitments (7/10, 7/10). Weakest on Nature & Biodiversity Impact and Controversies & Red Flags (3/10, 4/10).
11 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Where AbbVie sits among healthcare / pharmaceuticals peers.
Among the 15 major healthcare / pharmaceuticals brands we've scored, AbbVie is tied =8th of 15, with 1 other.
Score history begins 4 April 2026.
As AbbVie's score updates, the trajectory will appear here.
This score is not currently being contested.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
AbbVie is a US-based pharmaceutical company founded in 2013 through separation from Abbott Laboratories, headquartered in North Chicago. With $58B in FY2022 revenue, it develops treatments across immunology, oncology, virology, and neuroscience. AbbVie operates a global manufacturing and R&D footprint with complex supply chains typical of large-scale pharma.
Peer pharmaceutical company with comparable scale, supply chain complexity, and regulatory exposure.
View breakdown →Large-cap pharma peer; comparison point for nature & biodiversity assessment rigor and transparency.
View breakdown →Comparable pharma manufacturer; relevant for water and waste management practices in heavily regulated sector.
View breakdown →Diversified healthcare giant; shared regulatory penalty history and trade association climate alignment concerns.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Checking your suppliers?
Get your list scored in 48 hours →Been scored?
See what's behind your number →Nobody can pay us to change a number.